A phase IIa, randomized, open-label study evaluating the safety and efficacy of CreaVax-RA combined with traditional disease modifying anti-rheumatic drugs (DMARDs) therapy in patients with moderate to severe active rheumatoid arthritis despite DMARDs therapy

Trial Profile

A phase IIa, randomized, open-label study evaluating the safety and efficacy of CreaVax-RA combined with traditional disease modifying anti-rheumatic drugs (DMARDs) therapy in patients with moderate to severe active rheumatoid arthritis despite DMARDs therapy

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Dendritic cell vaccine-CreaGene (Primary) ; Disease-modifying antirheumatics
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms RIMMUNERA
  • Sponsors JW CreaGene
  • Most Recent Events

    • 16 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top